Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Chemocentryx Inc (CCXI)

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,422,734
  • Shares Outstanding, K 69,900
  • Annual Sales, $ 64,890 K
  • Annual Income, $ -55,360 K
  • 60-Month Beta 1.80
  • Price/Sales 39.92
  • Price/Cash Flow N/A
  • Price/Book 7.67
Trade CCXI with:

Options Overview Details

View History
  • Implied Volatility 82.61%
  • Historical Volatility 45.05%
  • IV Percentile 35%
  • IV Rank 11.36%
  • IV High 317.00% on 10/06/21
  • IV Low 52.58% on 12/17/20
  • Put/Call Vol Ratio 0.20
  • Today's Volume 2,241
  • Volume Avg (30-Day) 2,886
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 28,398
  • Open Int (30-Day) 52,107

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.35
  • Number of Estimates 6
  • High Estimate 0.05
  • Low Estimate -0.60
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +18.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.06 +5.96%
on 12/06/21
41.83 -16.26%
on 11/22/21
-5.12 (-12.75%)
since 11/05/21
3-Month
15.15 +131.26%
on 09/13/21
42.16 -16.91%
on 10/11/21
+19.11 (+120.04%)
since 09/03/21
52-Week
9.53 +267.58%
on 05/25/21
70.29 -50.16%
on 02/09/21
-22.44 (-39.05%)
since 12/04/20

Most Recent Stories

More News
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos

ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.

ENDP : 5.02 (+0.60%)
SRPT : 81.70 (+4.08%)
CPRX : 6.93 (+1.02%)
CCXI : 35.03 (+1.07%)
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)

SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s...

CCXI : 35.03 (+1.07%)
ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top

ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.

REGN : 625.00 (-1.60%)
ENDP : 5.02 (+0.60%)
ALKS : 22.20 (+0.73%)
CCXI : 35.03 (+1.07%)
ChemoCentryx to Participate in Two Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and...

CCXI : 35.03 (+1.07%)
ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 30.44% and 20.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CCXI : 35.03 (+1.07%)
What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

PRGO : 37.04 (+3.49%)
CCXI : 35.03 (+1.07%)
FGEN : 14.19 (+5.03%)
PETQ : 21.91 (-3.65%)
Should You Buy ChemoCentryx (CCXI) Ahead of Earnings?

ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CCXI : 35.03 (+1.07%)
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)

SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and...

CCXI : 35.03 (+1.07%)
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021...

CCXI : 35.03 (+1.07%)
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CCXI : 35.03 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

See More

Key Turning Points

3rd Resistance Point 38.32
2nd Resistance Point 36.88
1st Resistance Point 35.95
Last Price 35.03
1st Support Level 33.58
2nd Support Level 32.14
3rd Support Level 31.21

See More

52-Week High 70.29
Fibonacci 61.8% 47.08
Fibonacci 50% 39.91
Last Price 35.03
Fibonacci 38.2% 32.74
52-Week Low 9.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar